Exenatide

Exenatide is a synthetic version of exendin-4, a 39-amino acid peptide originally isolated from the saliva of the Gila monster lizard (Heloderma suspectum). It was the first GLP-1 receptor agonist to receive FDA approval (2005, as Byetta). Despite only 53% sequence homology to human GLP-1, exendin-4 is a full agonist at the human GLP-1 receptor and is naturally resistant to DPP-4 degradation. Available as twice-daily injection (Byetta) and once-weekly extended-release microsphere formulation (Bydureon), exenatide demonstrated the clinical viability of the GLP-1 agonist class, pioneering the incretin-based approach to diabetes and obesity treatment that culminated in semaglutide and tirzepatide.

Exenatide activates the GLP-1 receptor with comparable potency to native GLP-1 but with greatly enhanced metabolic stability (~2.4 hour half-life vs 2 minutes). It stimulates glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and promotes satiety through central GLP-1R activation. The C-terminal Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser extension (absent in mammalian GLP-1) confers DPP-4 resistance.

Type 2 Diabetes (Approved) FDA-approved as Byetta (2005) and Bydureon (2012). HbA1c reduction of 0.8-1.5%. The EXSCEL trial showed cardiovascular safety. Parkinson's Disease The Exenatide-PD trial showed improved motor scores and potential neuroprotective effects, with ongoing Phase 3 studies for Parkinson's disease. Alzheimer's Disease Preclinical and early clinical data suggest GLP-1R agonism may reduce neuroinflammation and amyloid pathology.

cAMP/PKA signaling in beta cells for insulin secretion. PI3K/Akt for beta cell survival. Central melanocortin and brainstem NTS pathways for appetite regulation. Vagal afferent signaling for gastric emptying delay.

Nausea (44%), vomiting (13%), diarrhea (13%) with twice-daily Byetta. Less GI effects with once-weekly Bydureon due to slower release. Injection site nodules with Bydureon microspheres. Pancreatitis risk rare. Thyroid C-cell warning (rodent data). Anti-exenatide antibodies develop in some patients.

Byetta pens store at 2-8°C; after first use, room temperature for 30 days. Bydureon microsphere kits store at 2-8°C. Both protect from light.

FDA-approved: Byetta (2005, twice-daily), Bydureon (2012, once-weekly). EMA and worldwide approvals. WADA-prohibited under S2 category.